Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Prepaid Assets (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Prepaid Assets for 6 consecutive years, with $6.3 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Prepaid Assets changed N/A year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Mar 2025, changed N/A, and an annual FY2023 reading of $9.9 million, up 1521.44% over the prior year.
  • Prepaid Assets was $6.3 million for Q1 2025 at Barinthus Biotherapeutics, down from $8.2 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $9.9 million in Q2 2022 and bottomed at $611000.0 in Q4 2022.
  • Average Prepaid Assets over 5 years is $6.0 million, with a median of $6.5 million recorded in 2021.
  • The sharpest move saw Prepaid Assets soared 22182.76% in 2021, then tumbled 90.54% in 2022.
  • Year by year, Prepaid Assets stood at $6.5 million in 2021, then crashed by 90.54% to $611000.0 in 2022, then surged by 1521.44% to $9.9 million in 2023, then dropped by 17.43% to $8.2 million in 2024, then decreased by 22.91% to $6.3 million in 2025.
  • Business Quant data shows Prepaid Assets for BRNS at $6.3 million in Q1 2025, $8.2 million in Q3 2024, and $9.9 million in Q4 2023.